Study: NCT05735704

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for HemaChip screening/diagnostic testing
Description: Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for HemaChip screening/diagnostic testing
Description: Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for HemaChip screening/diagnostic testing
Description: Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling for HemaChip screening/diagnostic testing
Description: Classification of a broad spectrum of blood cancers based on detection of epigenetic biomarkers from genomic DNA, cell-free (cf) DNA, exosomal DNA, RNA and non-coding RNA. The identified biomarkers will include proteins, metabolites, and other characteristic biomolecules.~Year 1: During the discovery phase, all tests will be conducted by JaxBio and TAU with the aid of technical service providers. At this stage, microarray measurements will be performed on a commercial platform that will be purchased from Agilent / Illumina. All reagents needed for the test will be either purchased or produced in-house.~Years 2-3: Throughout the second phase of the project, a custom targeted microarray, HemaChip will be developed and used for all tests. The HemaChip and custom reagents will be distributed to partners' labs and all tests will be conducted at the clinical sites. Additional validation tests will be conducted by JaxBio and TAU, as needed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone marrow sampling
Description: as part of the discovery stage, bone marrow samples will be obtained at Tel-Aviv Sourasky Medical Center (TASMC) from up to 50 MM patients and up to 50 AML patients that undergo bone marrow aspiration as part of the standard care procedure. Additionally, up to 50 bone marrow samples will be taken from healthy volunteers that will undergo hip or knee replacement surgery.